A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies
Latest Information Update: 06 Jul 2026
At a glance
- Drugs AZD 9829 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 01 Jul 2026 Status changed from active, no longer recruiting to completed.
- 05 Mar 2026 This trial has been completed in Spain.
- 05 Mar 2026 This trial has been terminated early in Germany and Italy due to Sponsor Decision.